repotrectinib NTRK
Selected indexed studies
- Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. (Nat Med, 2026) [PMID:41639379]
- Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. (JCO Precis Oncol, 2023) [PMID:37262390]
- Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome. (JCO Precis Oncol, 2024) [PMID:38271657]
_Worker-drafted node — pending editorial review._
Connections
repotrectinib NTRK is a side effect of
Sources
- Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer. (2024) pubmed
- Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. (2026) pubmed
- Response to Repotrectinib After Development of NTRK Resistance Mutations on First- and Second-Generation TRK Inhibitors. (2023) pubmed
- Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT Syndrome. (2024) pubmed
- NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors. (2024) pubmed
- Oncogenic fusions: Targeting NTRK. (2024) pubmed
- Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours. (2026) pubmed
- [Repotrectinib in advanced cancers with NTRK fusion after progression or not on a first TRK inhibitor]. (2025) pubmed
- Exposure-Response Analysis of Repotrectinib to Support the Dose Recommendation for Patients With ROS1-Positive NSCLC or NTRK-Positive Solid Tumors. (2025) pubmed
- PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia. (2026) pubmed